Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

Thu, 08th Apr 2021 02:20

* Policy shift will hold up vaccination campaign, says PM

* People with first shot should still get their second

* Italy, UK have suggested AstraZeneca shot age limits
(Adds quote from chief health officer, prime minister and adds
detail)

By Colin Packham and Jonathan Barrett

CANBERRA/SYDNEY, April 8 (Reuters) - Australia said on
Thursday it now recommends people under 50 should get Pfizer's
COVID-19 vaccine in preference to AstraZeneca's
shot, a policy shift that it warned would hold up its
inoculation campaign.

The move, a day after European regulators reiterated they
had found possible links between AstraZeneca's shot and reports
of very rare cases of blood clots, is a huge hurdle for
Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told
reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca
vaccine, usually within 4 to 10 days after that vaccine. But it
is serious, and it can cause up to a 25% death rate when it
occurs," he said.

Australia would advise health providers to only give a first
dose of the AstraZeneca vaccine to adults younger than 50 when
the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in
suggesting age limits for AstraZeneca's vaccine. But the
European regulators reaffirmed the importance of that shot in
protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without
any serious adverse events "can safely be given their second
dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will
delay Australia's inoculation timetable, but it was too soon to
say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will
need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine
and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to
people over 70. Those over 50 who opt for the Pfizer vaccine
will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine
for the vast majority of its near 26 million population -
expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind
schedule.

It had pledged to administer at least 4 million first doses
by the end of March, but could only deliver 670,000, with the
government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort,
underpinned by plans to make 50 million doses of AstraZeneca
vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other
nations because of its few infections, which stand at just under
29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus:
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Colin Packham and Jonathan Barrett; Editing by
Michael Perry, Clarence Fernandez and Andrew Heavens)

More News
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.